India M&A Uptick: Have The Planets Aligned?
Executive Summary
The recent uptick in M&A on the Indian pharmaceutical market points to tempered valuations and the potential for further consolidation. Scrip spoke to a cross-section of experts including investment bankers on deal street expectations, foreign interest in M&A and whether family-led Indian firms may now be more open to sell-offs.
You may also be interested in...
Deal Watch: Ionis Out-Licenses Pair Of Generation 2.5 Antisense Candidates
Janssen and French biotech Dynacure take licenses to antisense candidates arising from Ionis’ Generation 2.5 technology. Merck and Cue sign autoimmune partnership, while Bayer and PeptiDream ink discovery pact.
Merger-killing ego: does it strangle Indian pharma superpower ambitions before birth?
"Despite all the seeming cultural and other issues, if Dr Anji Reddy [the founder of Dr Reddy's Laboratories] and Dr Yusuf Hamied [Cipla's chairman and managing director] can come together and merge their businesses, it will be a great day not only for Indian pharma but for the country." So says Dr Brian Tempest, an ex-CEO of Ranbaxy Laboratories and currently an advisor to MAPE, a mid-market investment bank, and the United Nations Conference on Trade and Development, among other positions.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.